Expertise in
26
conditions

Dr. James E. Radford

Oncology
Office
800 N Justice St, 
Hendersonville, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
26
conditions
Office
800 N Justice St, 
Hendersonville, NC 

Overview

James Radford is an Oncologist practicing medicine in Hendersonville, North Carolina.

Dr. Radford is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Neuroendocrine Tumor, Colorectal Cancer, Urothelial Cancer, and Endoscopy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 95 clinical trials. Dr. Radford is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
800 N Justice St, Hendersonville, NC 28791
Other Locations
Hendersonville Hematology and Oncology@Pardee
1824 Pisgah Dr, Hendersonville, NC 28791

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

94 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
View 8 Less Clinical Trials

1 Total Publications

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2013
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Gynecologic Oncology (Spartanburg)

101 East Wood Street, Floor 3, 
Spartanburg, SC 
 (38.6 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carlton Schwab is an Oncologist practicing medicine in Spartanburg, South Carolina. He has been practicing medicine for over 17 years. Dr. Schwab is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Bladder Reconstruction, and Hernia Surgery. Dr. Schwab is board certified in American Board Of Obstetrics & Gynecology, (Obstetrics & Gynecology), and (Obstetrics & Gynecology, Gynecologic Oncology). Dr. Schwab is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Hope Women's Cancer Center

100 Ridgefield Ct, 
Asheville, NC 
 (15.9 miles away)
828-670-8403
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Vanderkwaak is an Oncologist practicing medicine in Asheville, North Carolina. Dr. Vanderkwaak is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Malignant Mixed Mullerian Tumor, Ovarian Cancer, Virilizing Ovarian Tumor, Hernia Surgery, and Splenectomy. Dr. Vanderkwaak is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Hope Women's Cancer Center

100 Ridgefield Ct, 
Asheville, NC 
 (15.9 miles away)
828-670-8403
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ashley Case is an Oncologist practicing medicine in Asheville, North Carolina. Dr. Case is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Vulvar Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Lymphadenectomy, and Salpingo-Oophorectomy. Dr. Case is currently accepting new patients.

Frequently Asked Questions about Dr. James E. Radford

How do I make an appointment with Dr. James E. Radford?

You can book an appointment with Dr. James E. Radford by calling their office at 828-692-8045. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James E. Radford a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James E. Radford is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James E. Radford specialize in?

While Dr. James E. Radford is a Oncology, they have specific expertise in Lung Cancer, Neuroendocrine Tumor, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. James E. Radford participate in research or clinical trials?

Yes. Dr. James E. Radford has published 1 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. James E. Radford's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James E. Radford accept my insurance?

Dr. James E. Radford accepts most major insurance plans, including Anthem BCBS and Change Healthcare. We recommend calling the office directly at 828-692-8045 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Radford's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 77 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile